Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Status: | Completed |
---|---|
Conditions: | Constipation, Irritable Bowel Syndrome (IBS) |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | Any |
Updated: | 11/18/2012 |
Start Date: | August 2010 |
End Date: | October 2012 |
Contact: | Lina Nahlawi |
Email: | lnahlawi@umich.edu |
Phone: | (734)936-2761 |
A Pilot Study to Assess the Effects of Lubiprostone on Gastrointestinal and Colonic Motility and pH in Patients With the Irritable Bowel Syndrome and Constipation (IBS-C)
Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or
discomfort in association with altered bowel habit. IBS is further subcategorized as three
types according to the predominant bowel movement pattern: IBS with constipation (IBS-C),
IBS with diarrhea (IBS-D), and mixed-IBS (IBS-M). The exact causes of IBS remain
incompletely understood, but proposed mechanisms include abnormal motility, visceral
hypersensitivity, abnormal brain-gut interactions, psychological distress, and altered GI
tract motility.
Lubiprostone, a novel drug that works by activating the colonic ClC-2 chloride channel, has
been approved for use in patients with chronic idiopathic constipation and recently approved
for the treatment of IBS-C in women aged 18 and older. By activating the ClC-2 chloride
channel in the colon, lubiprostone allows more fluid secretion into the intestinal lumen
which leads to softer stool consistency. In phase III clinical trials, patients with IBS-C
receiving lubiprostone have reported improvements in many symptoms such as abdominal pain
and constipation. However, there is limited physiologic data to explain how exactly
lubiprostone improves IBS-C symptoms.
The Smartpill is a novel non-digestible capsule that is capable of measuring intraluminal
pH, pressure, and temperature in the gastrointestinal (GI) tract. Smartpill has been shown
to accurately measure whole gut as well as regional (i.e. stomach, small bowel, colon)
transit time.
The primary aim of this study is to determine the effects of lubiprostone on whole GI tract
transit, colonic transit, motility, and intraluminal pH in patients with IBS-C through
evaluation with the Smartpill. The investigators propose to study the effect of lubiprostone
vs. placebo on these parameters, and secondarily to evaluate changes in these parameters
with differing doses of lubiprostone.
The investigators hypothesize that lubiprostone will increase whole GI and colonic transit
compared to placebo in patient with IBS. the investigators do not expect a change in
intraluminal pH with lubiprostone compared to placebo.
Inclusion Criteria:
- Males or females >18 years of age
- Meet Rome III criteria for IBS[2]:
- Recurrent abdominal pain or discomfort at least 3 days per month in the last 3
months associated with 2 or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency
3. Onset associated with a change in form (appearance) of stool
- *Criteria fulfilled for the last 3 months with symptom onset at least 6 months
prior to diagnosis
- Fulfill the Rome III stool consistency criteria for IBS-C[2]
- Hard or lumpy stools for >25% of bowel movements
- Loose (mushy) or watery stools for <25% of bowel movements
- Capable of independently completing all requirements of the study including returning
for required visits
- Able to provide written informed consent for study participation
- Willing to discontinue prohibited medications during study participation
- Documentation of a normal colonoscopy within last 5 years if over age 50 years (or
sigmoidoscopy if less than age 50)
- Documentation of normal TSH, CBC and electrolyte panel within prior 3 years
- Females of childbearing potential must have a negative urine or serum pregnancy test
at screening
- Females of childbearing potential must use an effective means of contraception during
the course of the study
- Hormonal (oral, injectable, implantable, cervical/vaginal rings or patches)
- Double-barrier (condoms and/or diaphragm with spermicides) or intrauterine
devices provided under the care of a health care professional
- Abstinence, in this case documentation of counseling will be recorded
Exclusion Criteria:
- Unable to understand or provide written informed consent
- Pregnant or nursing
- Patients with IBS-D, IBS-M or unsubtyped IBS by Rome III criteria[2]
- IBS with diarrhea (IBS-D)
1. Loose (mushy) or watery stools for >25% of bowel movements
2. Hard or lumpy stools for <25% of bowel movements
- Mixed IBS (IBS-M)
1. Hard or lumpy stools >25% of bowel movements
2. Loose (mushy) or watery stools for >25% of bowel movements
- Unsubtyped IBS
1. Insufficient abnormality of stool pattern to meet criteria for IBS-C, IBS-D or
IBS-M
- Documented allergy or intolerance to lubiprostone
- Failure of balloon expulsion test
- Inability to expel 50cc balloon within 1 minute
- Use of drugs known to affect gastrointestinal motility
1. Laxatives (stable doses of fiber taken for minimum of 4 weeks will be allowed)
Osmotic laxatives:
Magnesium hydroxide, Polyethylene glycol,Lactulose, Sorbitol
Stimulant laxatives:
Bisacodyl, Anthraquinones (senna), Misoprostol
2. Prokinetic agents:
Metoclopramide, domperidone, erythromycin
3. Anti-diarrheal agents:
Loperamide, Diphenoxylate, Bismuth
4. Anti-spasmotics:
Dicyclomine, Hyoscyamine
5. Opioid, narcotic, opioid/narcotic-containing analgesics:
Morphine, Hydrocodone, Codeine, Methadone, Propoxyphene
6. Probiotics
7. Systemic antibiotics within last 3 months
8. Recently initiated antidepressants (stable dose for >2 months for non-GI
conditions will be allowed)
9. Benzodiazepines * Subjects taking prohibited medications will be required to
stop these at the screening visit and remain off of them until completion of the
study.
- Initiation of dietary changes potentially altering bowel transit within 4 weeks
- Comorbid medical problems that may affect gastrointestinal transit or motility
1. Previous surgery involving the stomach, small bowel or colon (prior
appendectomy, cholecystectomy, polypectomy allowed)
2. Previous history of small bowel obstruction for any reason
3. History of any gastrointestinal malignancy
4. History of dyssynergic defecation
5. Unexplained nausea and vomiting
6. History of inflammatory bowel disease (Crohn's or ulcerative colitis)
7. History of microscopic colitis (lymphocytic or collagenous colitis)
8. History of Hirschsprung's disease
9. Severe or complicated diverticular disease
10. Chronic pancreatitis
11. History of celiac disease
12. History of eating disorders (anorexia nervosa or bulimia)
13. Cirrhosis
14. Chronic hepatitis B or C infection
15. HIV infection
16. Diabetes
17. Systemic sclerosis (scleroderma)
18. Amyloidosis
19. Untreated thyroid disease
20. Chronic pulmonary disease
21. Severe renal insufficiency or renal failure
22. Current or recent history (within last 6 months) of:
Diverticulitis, Duodenal or gastric ulcer, Acute pancreatitis, Ileus
- Contraindications to SmartPill® (in addition to above):
Cardiac pacemaker, defibrillator, or other implanted electromagnetic device, Known
Zenker's diverticulum, Dysphagia
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health System The University of Michigan is home to one of the...
Click here to add this to my saved trials